Yahoo Web Search

Search results

1. • 

     Sanofi forecasts moderate profit growth on Dupixent demand

     Reuters via Yahoo News· 1 year ago

     (Reuters) -Sanofi forecast moderate earnings growth that undershot expectations, saying demand for...

2. • 

     Sanofi's Dupixent wins U.S. approval for bigger use

     Reuters via Yahoo News· 2 years ago

     There are more than 160,000 patients in the United States living with eosinophilic esophagitis (EoE), according to Sanofi. Sanofi's regulatory filing for...

3. • 

     Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

     Reuters via Yahoo News· 1 year ago

     (Reuters) -Sanofi's asthma drug Dupixent met all targets in a trial to treat "smoker's lung",...

4. • 

     Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

     Zacks via Yahoo Finance· 1 year ago

     Regeneron Pharmaceuticals, Inc. REGN is having a good run, with shares gaining 16.4% in the year so...

5. • 

     ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

     Zacks via Yahoo Finance· 1 month ago

     ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...

6. • 

     Sanofi lifts earnings outlook on new drug launches, Dupixent sales

     Reuters via Yahoo Finance· 9 months ago

     (Reuters) -French drugmaker Sanofi on Friday increased its guidance for full-year earnings, citing...

7. • 

     Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers

     Investor's Business Daily· 5 months ago

     Regeneron Pharmaceuticals' high-dose Eylea is off to a strong start in the U.S., the company said...

8. • 

     Could Regeneron Stock Help You Retire a Millionaire?

     Motley Fool via Yahoo Finance· 3 months ago

     There are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among...

9. • 

     Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB

     Zacks via Yahoo Finance· 2 years ago

     The biotech sector has been in the spotlight in the past week, with regular pipeline and regulatory...

10. • 

      Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK

      Zacks via Yahoo Finance· 1 year ago

      This week, Eli Lilly’s LLY candidate, solanezumab, failed to prevent Alzheimer’s in a study. Merck’s...